Tumor necrosis factor-α in Guillain-Barré syndrome, friend or foe? (Q39000208)

8 September 2017

1 reference

title

Tumor necrosis factor-α in Guillain-Barré syndrome, friend or foe? (English)

1 reference

8 September 2017

Guillain–Barré syndrome

0 references

Jingdian Zhang

2

0 references

author name string

Ying Wang

1

1 reference

8 September 2017

Peijuan Luo

3

1 reference

8 September 2017

Jie Zhu

4

1 reference

8 September 2017

Jiachun Feng

5

1 reference

8 September 2017

Hong-Liang Zhang

6

1 reference

8 September 2017

language of work or name

English

0 references

publication date

6 November 2016

1 reference

Expert Opinion on Therapeutic Targets

8 September 2017

1 reference

8 September 2017

21

1 reference

8 September 2017

1

1 reference

8 September 2017

103-112

1 reference

Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis

8 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Risk of Guillain-Barré syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Guillain-Barré syndrome after exposure to influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Guillain-Barré syndrome and influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Th1/Th2/Th17/Treg cytokines in Guillain-Barré syndrome and experimental autoimmune neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

The role of cytokines in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Selective expression and cellular localization of pro-inflammatory chemokine ligand/receptor pairs in the sciatic nerves of a severe murine experimental autoimmune neuritis model of Guillain-Barré syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Axonal Guillain-Barré syndrome: concepts and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

21 January 2018

Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Sural sparing pattern discriminates Guillain-Barré syndrome from its mimics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Electrophysiological studies in the Guillain-Barré syndrome: distinguishing subtypes by published criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Patterns and severity of conduction abnormalities in Guillain-Barre syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Attenuated EAN in TNF-α deficient mice is associated with an altered balance of M1/M2 macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Immune circuitry in the peripheral nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

The role of macrophages in immune-mediated damage to the peripheral nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

An endotoxin-induced serum factor that causes necrosis of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

TNF-R1 signaling: a beautiful pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

T cells as sources and targets of TNF: implications for immunity and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Incidence of Guillain-Barré syndrome among patients with Campylobacter infection: a general practice research database study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

The effect of TNF-alpha, FcγR and CD1 polymorphisms on Guillain-Barré syndrome risk: evidences from a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Tumor necrosis factor alpha 308 G/A polymorphism and Guillain-Barré syndrome risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Genetics of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Polymorphism of CD1 and SH2D2A genes in inflammatory neuropathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Recent developments and future directions in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Guilt by association: HLA-B27 and ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Sialylation of Campylobacter jejuni endotoxin promotes dendritic cell-mediated B cell responses through CD14-dependent production of IFN-β and TNF-α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Harmful effects of anti-GalNAc-GD1a antibodies and TNF-alpha on rat dorsal root ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

TH1 and TH2 response to Campylobacter jejuni antigen in Guillain-Barre syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Cerebrospinal fluid biomarkers in Guillain-Barré syndrome--where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Tumor necrosis factor-alpha antagonists and neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Severe Guillain-Barré syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Can IFN-γ be a therapeutic target in Guillain-Barré syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Cytokine dichotomy in peripheral nervous system influences the outcome of experimental allergic neuritis: dynamics of mRNA expression for IL-1 beta, IL-6, IL-10, IL-12, TNF-alpha, TNF-beta, and cytolysin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

TNF-alpha receptor 1 deficiency reduces antigen-presenting capacity of Schwann cells and ameliorates experimental autoimmune neuritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Cdc42 GTPases facilitate TNF-α-mediated secretion of CCL2 from peripheral nerve microvascular endoneurial endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Tumour necrosis factor α enhances CCL2 and ICAM-1 expression in peripheral nerve microvascular endoneurial endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Keratan sulfate expression in microglia is diminished in the spinal cord in experimental autoimmune neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Role of TNF-alpha in high-dose antigen therapy in experimental autoimmune neuritis: inhibition of TNF-alpha by neutralizing antibodies reduces T-cell apoptosis and prevents liver necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Soluble TNFR1 inhibits the development of experimental autoimmune neuritis by modulating blood-nerve-barrier permeability and inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Therapeutic potential of atorvastatin-modified dendritic cells in experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells and NKR-P1(+) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Pioglitazone, PPARγ agonist, attenuates experimental autoimmune neuritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Curcumin ameliorates rat experimental autoimmune neuritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Administration of dehydroepiandrosterone ameliorates experimental autoimmune neuritis in Lewis rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Berberine ameliorates experimental autoimmune neuritis by suppressing both cellular and humoral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

Tumour necrosis factor and lymphotoxin genes map close to H–2D in the mouse major histocompatibility complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1258402

10.1080/14728222.2017.1258402

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference